MENA – the Middle East and North Africa. As a region, it's got everything a drugmaker could want. An expanding and aging population. Unmet medical need. A growing middle class. The desire and the ability to pay for branded and generic therapies. Read More
In mice genetically predisposed to develop Alzheimer's disease, stem cell function is disturbed due to problems in lipid processing that lead to the accumulation of fat droplets in the brain, researchers from the University of Montreal have found. Read More
TOKYO – Domestic and multinational pharmaceutical companies want Japan to maintain a scheme that adds price premiums to certain drugs, which makes it easier for drug companies to recoup research and development costs. Read More
Cipla Ltd., through its UK unit, Cipla EU, inked agreements to acquire the U.S.-based generics company, Invagen Pharmaceuticals Inc., and consulting firm Exelan Pharmaceuticals Inc., in an all-cash deal valued at $550 million. Read More
Allergan plc spotted an opportunity to add an implantable shunt technology to its eye care offering through a $300 million cash acquisition of privately held Aquesys Inc., of Aliso Viejo, Calif. Read More
DUBLIN – European life sciences firms raised €23 million (US$26 million) in 42 crowdfunding campaigns over the last five years, according to the first ever analysis of the field, published last week by Biocom AG, a Berlin-based consultancy and research firm. Read More
Marketing in MENA requires a deep understanding of the culture of the various countries and a sensitivity to their distinct needs. The geopolitical instability and diverse regulatory schemes also may require manufacturing redundancies and extensive diplomatic know-how. Read More
There's a lot to be said for partnering with a domestic company in an emerging market. Topping the list are community involvement, first-hand knowledge of the health care systems and an established relationship with doctors. Read More
Biotime Inc., of Alameda, Calif., said the Tel Aviv Stock Exchange approved the listing of the company's common stock, beginning Sept. 8, under the ticker BTX. Read More
Coherus Biosciences Inc., of Redwood City, Calif., provided an update of its clinical programs, including a plan to increase the total number of healthy subjects to be enrolled in its immunogenicity study as part of its biologics license application-enabling clinical program for CHS-1701 (pegfilgrastim [Neulasta biosimilar]), in concurrence with the FDA. Read More
Scientists from the Belgian University of Ghent have identified an enzyme whose activation protected against the development of allergies during chronic low-level exposure to allergens. Read More
